| Chemical Properties | Back Directory | [storage temp. ]
4°C, stored under nitroge | [solubility ]
Ethanol: soluble | [form ]
A solid | [color ]
Light brown to brown | [Water Solubility ]
Water: 100 mg/mL (174.23 mM) | [SMILES]
FC(F)(C1=CC=C2SC3=C(N(CCCN4CCN(CC4)CCN(C)C)C2=C1)C=CC=C3)F.[3HCl] |
| Hazard Information | Back Directory | [Uses]
ZZW-115 hydrochloride is a potent NUPR1 inhibitor, with a Kd of 2.1 μM. ZZW-115 hydrochloride induces tumor cell death by necroptosis and apoptosis. Anticancer activity[1][2]. | [Biological Activity]
ZZW-115 is a nuclear protein 1 (NUPR1) inhibitor th at suppresses NUPR1-dependent cancer growth in vitro (IC50 from 0.84 μM/ANOR to 4.93 μM/HN14 among 11 pancreatic ductal adenocarcinoma cultures) and in mice in vivo (5 mg/kg q.d. or q.a.d. via i.p.) via necroptosis and ferroptosis induction. ZZW-115 blocks importins-mediated NUPR1 nuclear translocation by directly targeting NUPR1 nuclear location signal (NLS) region (Kd = 2.1 μM by calorimetric titration). | [in vivo]
ZZW-115 hydrochloride (0.5-5 mg/kg; injection; daily for 30 days) inhibits the growth of pancreatic xenografted tumors[1].
?
ZZW-115 hydrochloride (5 mg/kg for 30 days; immunocompetent C57BL/6 mice were orthotopically implanted with Panc02 cells) treatment shows the tumor size is almost unmeasurable in some cases[1]. | Animal Model: | NMRI-Foxn1nu/Foxn1nu mice (nude mice) xenografted with MiaPaCa-2 cells [1] | | Dosage: | 5, 2.5, 1.0, or 0.5 mg/kg | | Administration: | Injection; daily for 30 days | | Result: | When the mice were injected with 5 mg/kg ZZW-115 hydrochloride, the tumors stopped growing a few days after treatment and their size decreased progressively, almost disappearing at the end of the treatment.
|
| [References]
[1] Santofimia-Casta?o P, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129(6):2500-2513. Published 2019 Mar 28. DOI:10.1172/JCI127223
[2] Santofimia-Casta?o P, et al. Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. Cells. 2019;8(11):1453. Published 2019 Nov 17. DOI:10.3390/cells8111453 |
|
|